SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 219.85 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 160.64 |
| Book Value / Share | 1.71 |
| Price / Book | n/a |
| NCAV ($M) | 102.98 |
| NCAV / Share | 1.10 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.33 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | -0.35 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.22 |
| Current Ratio | 9.22 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 125.15 |
| Assets | 182.81 |
| Liabilities | 22.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 14.80 |
| Operating Income | -53.62 |
| Net Income | -54.23 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -60.41 |
| Cash from Investing | 65.64 |
| Cash from Financing | 43.25 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | AFFiRiS AG | 6.66 | -2.18 | |
| 13G/A | Biotechnology Value Fund L P | 14.80 | 96.16 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 18,436 | 106,117 | 17.37 | |
| 16,034 | 160,428 | 9.99 | |
| 14,052 | 11,215 | 125.30 | |
| 17,859 | 17,550 | 101.76 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACAB – Atlantic Coastal Acquisition Corp. II | ACET – Adicet Bio, Inc. |
| ACRV – Acrivon Therapeutics, Inc. | ADMA – ADMA Biologics, Inc. |
Financial data and stock pages provided by
Fintel.io